Cite
Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.
MLA
Lambe, Cécile, et al. “Long-Term Treatment with Teduglutide: A 48-Week Open-Label Single-Center Clinical Trial in Children with Short Bowel Syndrome.” The American Journal of Clinical Nutrition, vol. 117, no. 6, June 2023, pp. 1152–63. EBSCOhost, https://doi.org/10.1016/j.ajcnut.2023.02.019.
APA
Lambe, C., Talbotec, C., Kapel, N., Barbot-Trystram, L., Brabant, S., Nader, E. A., Pigneur, B., Payen, E., & Goulet, O. (2023). Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome. The American Journal of Clinical Nutrition, 117(6), 1152–1163. https://doi.org/10.1016/j.ajcnut.2023.02.019
Chicago
Lambe, Cécile, Cécile Talbotec, Nathalie Kapel, Laurence Barbot-Trystram, Séverine Brabant, Elie Abi Nader, Bénédicte Pigneur, Elise Payen, and Olivier Goulet. 2023. “Long-Term Treatment with Teduglutide: A 48-Week Open-Label Single-Center Clinical Trial in Children with Short Bowel Syndrome.” The American Journal of Clinical Nutrition 117 (6): 1152–63. doi:10.1016/j.ajcnut.2023.02.019.